Schedule of Sale of Business (Details) - Interpace Pharma Solutions [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price			$ 7,000
Earnout received			1,043
Working capital adjustment, net		(117)	(766)
Less: transaction costs			(307)
Total net consideration		(117)	6,970
Assets and liabilities disposed of, net	[1]		(6,970)
Gain (loss) on sale		$ (117)

[1] includes goodwill and intangible assets written down prior to the Transaction. The goodwill write-down was approximately $8.4 million and the write-down of intangible assets was approximately $3.8 million.